SCHEMBL25325337

SCHEMBL25325337

O=C(O)c1ccccc1CN1CC2(C1)CN(C(=O)N1CC3(CC(c4nnc(C5CC5)[nH]4)C3)C1)C2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.40
▸ BRD4 O60885 4/20 0.33
▸ HRH2 P25021 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ CCR3 P51677 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ SIRT1 Q96EB6 1/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ NFE2L2 Q16236 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2D6 P10635 2/20 0.32
▸ SCD5 Q86SK9 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ MGLL Q99685 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326355 0.89 SIRT1 (0.36) ALDH1A1SIRT1CYP3A4CYP2D6CYP2C19
SCHEMBL25324883 0.89 CBLB (0.33) BRD4CYP3A4CYP2D6SCD5CYP2C19
SCHEMBL25323137 0.83 CYP3A4 (0.30) CYP3A4CYP2D6
SCHEMBL25326089 0.83 NR3C1 (0.34) CNR2CYP3A4CYP2D6CYP2C19
SCHEMBL25325561 0.80 DRD3 (0.42) ALDH1A1
SCHEMBL25324739 0.79 KMT2A (0.45) ALDH1A1KCNH2NPC1RAB9ACYP2D6
SCHEMBL25326091 0.79 ALDH1A1 (0.39) ALDH1A1
SCHEMBL27150741 0.78 MGLL (0.51) ALDH1A1BRD4HRH2HRH1CCR3
SCHEMBL25326561 0.77 ALPI (0.35) ALDH1A1MGLL
SCHEMBL30553160 0.77 CD274 (0.33) CYP3A4CYP2D6CYP2C19MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 ALDH1A1 411/4885BRD4 419/4885HRH2 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback